EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity
Open Access
- 18 March 2021
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 137 (11), 1468-1477
- https://doi.org/10.1182/blood.2020008520
Abstract
Primary central nervous system lymphoma (PCNSL) is confined to the brain, eyes, and cerebrospinal fluid without evidence of systemic spread. Rarely, PCNSL occurs in the context of immunosuppression (eg, posttransplant lymphoproliferative disorders or HIV [AIDS-related PCNSL]). These cases are poorly characterized, have dismal outcome, and are typically Epstein-Barr virus (EBV)-associated (ie, tissue-positive). We used targeted sequencing and digital multiplex gene expression to compare the genetic landscape and tumor microenvironment (TME) of 91 PCNSL tissues all with diffuse large B-cell lymphoma histology. Forty-seven were EBV tissue-negative: 45 EBV− HIV− PCNSL and 2 EBV− HIV+ PCNSL; and 44 were EBV tissue-positive: 23 EBV+ HIV+ PCNSL and 21 EBV+ HIV− PCNSL. As with prior studies, EBV− HIV− PCNSL had frequent MYD88, CD79B, and PIM1 mutations, and enrichment for the activated B-cell (ABC) cell-of-origin subtype. In contrast, these mutations were absent in all EBV tissue-positive cases and ABC frequency was low. Furthermore, copy number loss in HLA class I/II and antigen-presenting/processing genes were rarely observed, indicating retained antigen presentation. To counter this, EBV+ HIV− PCNSL had a tolerogenic TME with elevated macrophage and immune-checkpoint gene expression, whereas AIDS-related PCNSL had low CD4 gene counts. EBV-associated PCNSL in the immunosuppressed is immunobiologically distinct from EBV− HIV− PCNSL, and, despite expressing an immunogenic virus, retains the ability to present EBV antigens. Results provide a framework for targeted treatment.Keywords
This publication has 71 references indexed in Scilit:
- Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System LymphomasClinical Cancer Research, 2012
- Age, gender, and racial differences in incidence and survival in primary CNS lymphomaBritish Journal of Cancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern EraJournal of Clinical Oncology, 2010
- Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphomaLeukemia & Lymphoma, 2008
- Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trialBlood, 2007
- Immunity, Homing and Efficacy of Allogeneic Adoptive Immunotherapy for Posttransplant Lymphoproliferative DisordersAmerican Journal of Transplantation, 2007
- HIV Patients Developing Primary CNS Lymphoma Lack EBV-Specific CD4+ T Cell Function Irrespective of Absolute CD4+ T Cell CountsPLoS Medicine, 2007
- Persistence of the Epstein–Barr Virus and the Origins of Associated LymphomasThe New England Journal of Medicine, 2004
- B cells under influence: transformation of B cells by Epstein–Barr virusNature Reviews Immunology, 2003